Named in 1 fund letter, by J Capital Research.
| J Capital Research | 1 | 2021–2021 |
| ChromaDex (CDXC): Unhealthy | Anne Stevenson-Yang argues that ChromaDex lifts its share price with distribution announcements that yield few sales, such as a Walmart deal announced twice in 2021 and a Nestle deal that brought $559,000 in two years, so insiders can sell. | J Capital Research | J Capital Research | Q2 2021 |